The exemplary leadership from our board of directors is invaluable as NCCN defines and advances high-quality, high-value, patient-centered cancer care around the world," said NCCN CEO Crystal S. Denlinger, MD, who took on the role in October of 2023."Their steady guidance during a transitional time helps us maintain our highly trusted, continuously updated, evidence-based, expert consensus recommendations for cancer care, which were accessed more than 15 million times in 2023 alone.I look forward to working even more closely with Matt and Chris and relying on the substantial expertise, caring, and leadership they bring to these positions."Dr. Kalaycio is a leading expert in hematology and medical oncology who specializes in the treatment of leukemia, hematopoietic cell transplantation, and CAR T-cell therapy.He is Vice Chair of Cleveland Clinic Taussig Cancer Institute and a professor of medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University."NCCN is committed to ensuring that all cancer patients receive the latest evidence-based treatment options by not only informing healthcare providers of available treatments but also offering education and support to the patients and their caregivers," said Dr. Kalaycio."
No takes yet. Share an insight, caveat, or question.
Kalaycio et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: